Roche is a recognized global leader in developing products that help mitigate the devastation of serious diseases and prolong the lives of patients diagnosed with cancer, HIV/AIDS, heart disease, stroke and other serious conditions. Roche Canada has a range of prescription drug products in the following fields: Anemia & Vascular Access Oncology Paediatrics Rheumatoid Arthritis Transplantation Urgent Care Virology
Anemia & Vascular Access Roche Canada has been a leader in bringing life saving therapies to hospital based patients for more than 50 years. This commitment continues through the delivery of therapeutic treatments for patients with vascular access issues. Vascular Access Products:  Cathflo®
Oncology For years Roche has been a recognized global leader in the delivery of oncology therapies. We have built an extensive portfolio of oncology therapies that deliver proven survival benefits for cancer patients. Our unique approach to developing cancer therapies integrates both pharmaceuticals and diagnostics, thereby enabling us to pioneer a number of groundbreaking products that have made a significant difference in the lives of individuals diagnosed with lymphoma, breast, colorectal or lung cancer. These targeted anti-cancer treatments have become the standard of care for practitioners across Canada. Oncology Products:  Avastin®  Herceptin®  Rituxan®  Tarceva®  Xeloda®
Paediatrics Roche is dedicated to developing leading biological therapeutics that address significant unmet medical needs in the paediatric community. These therapies have been proven to extend and improve the quality of life for many children. Human Growth Hormone Products:  Nutropin® / Nutropin AQ Pen® Cartridge  Pulmozyme®
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an emerging area of research and development at Roche. Roche's work with Rituxan® — a leading targeted treatment for non-Hodgkin's lymphoma — has led to a major breakthrough in the management of RA. As part of our commitment to the treatment of inflammatory disease, Roche is continuing to work on three additional compounds specifically targeted at treating RA. Rheumatoid Arthritis Products:  Rituxan®
Transplantation Roche brought its first transplantation drug to the market in 1995. Its novel mechanism of action helps prevent rejection for patients receiving transplants, which led to further research and the development of the first humanized monoclonal antibody for use in kidney transplants. Transplant Products:  CellCept®  Cytovene®  Valcyte®  Zenapax®
Urgent Care Roche Canada prides itself in partnering with healthcare professionals to manage serious medical conditions and improve the health of Canadians. The Urgent Care Business Unit is comprised of a dedicated team of individuals managing the following products for treatment of acute myocardial infarction, stroke and influenza: Thrombolytic Products:  Activase® rt-PA  TNKase® Antiviral Products:  Tamiflu® ACE Inhibitor Products:  Inhibace®  Inhibace® Plus Antibiotic Products:  Rocephin® Antiobesity Products:  Xenical® Dermatology Products:  Accutane™ Roche®
Virology Roche has had a long history in developing innovative therapies for the treatment of HIV/AIDS and hepatitis B and C, and continues to lead the industry in introducing products that have proven highly effective in stemming the progress of these diseases and extending patients' lives. Our infectious disease therapies have delivered proven survival benefits for patients. This has been achieved through our unique approach that examines the genetic and molecular structure of these diseases to provide tailored treatment solutions, as well as an improved standard of care worldwide for people living with HIV/AIDS and hepatitis. Virology (HIV/AIDS and Hepatitis) Products:  Fuzeon®  Invirase®  Pegasys®  Pegasys RBV®